Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation

Journal of B.U.ON.

Volumn 14, Issue 4, 2009, Pages 629-634

  Igdem, Sefik ^a   Abacioglu, U ^b   Cetin, L ^b   Alco, G ^c   Akgun, Z ^b   Sengoz, M ^b   Bekiroglu, N ^b   Turkan, S ^c   Okkan, S ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c Metropolitan Hospital   (Turkey)

Author keywords

Core biopsies; External beam radiotherapy; Percent positive cores; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANTIGEN DETECTION; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREOPERATIVE EVALUATION; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RADIATION RESPONSE; RATING SCALE; TREATMENT DURATION; TREATMENT FAILURE; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 75149131743     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. D'Amico AV, Whittington R, Kaplan I et al. Equivalent biochemical failure free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of 4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997; 37:1053-1058.
2. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-771.
3. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000; 55:85-90.
4. Zelefsky MJ, Fuks Z, Hunt M et al. High dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53:1111-1116.
5. D'Amico AV, Whittington R, Malkowicz SB et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18:1164-1172.
6. D'Amico AV, Schultz D, Silver B et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2001 ; 49:679-684.
7. Selek U, Lee A, Levy L, Kuban DA. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003; 57:963-967.
8. Wong W, Schild S, Vora S, Halyard MY. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60:24-29.
9. ASTRO. Consensus Statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phy 1997; 37: 1035-1041.
10. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-500.
11. Neter J, Wasserman W, Kutner MH (Eds). Applied linear regression models. Homewood, IL: RD Irwin, 1983.
12. D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997; 158: 1422-1426.
13. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969-974.
14. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151:640-645.
15. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate. The influence of preoperative and pathologic findings on biochemical disease free outcome. Urology 1994; 43:828-833.
16. Yoon JH, Chen MH, Renshaw AA, Richie JP, D'Amico AV. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate risk prostate cancer. Urology 2002; 60:454-457.
17. Auzanneau C, Irani J, Ouaki F et al. Percentage of positive biopsy cores as a predictor of clinical outcome in prostate cancer treated with androgen deprivation therapy. Eur Urol 2004; 2 (Suppl): 224 (abstr).
18. D'Amico AV, Renshaw AA, Cote K et al. Impact of the percentage of positive prostate cores on prostate cancer specific mortality for patients with low or favorable intermediate risk disease. J Clin Oncol 2004; 22:3726-3732.
19. Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. The percentage of positive cores is not an appropriate risk factor for prostate radiotherapy to ≥ 72Gy. Int J Radiat Oncol Biol Phys 2005; 63 (Suppl 1): S200 (abstr).
20. Roach M, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965-974.